Shlomo Lewkowicz

Endobetix Ltd. develops a nonsurgical implant that mimics the hormonal benefits offered by bariatric surgery. It offers Endobetix Bile Diversion Device which changes the hormonal balance and induces the release of key hormones such as GLP-1 to improve glucose tolerance and reduce fat absorption. The company was founded by Chen Porat, Pierre Sharvit, and Shlomo Lewkowicz in 2012 and is headquartered in Misgav, Israel.

Endobetix Ltd. develops a nonsurgical implant that mimics the hormonal benefits offered by bariatric surgery. It offers Endobetix Bile Diversion Device which changes the hormonal balance and induces the release of key hormones such as GLP-1 to improve glucose tolerance and reduce fat absorption. The company was founded by Chen Porat, Pierre Sharvit, and Shlomo Lewkowicz in 2012 and is headquartered in Misgav, Israel.

Endobetix Ltd. develops a nonsurgical implant that mimics the hormonal benefits offered by bariatric surgery. It offers Endobetix Bile Diversion Device which changes the hormonal balance and induces the release of key hormones such as GLP-1 to improve glucose tolerance and reduce fat absorption. The company was founded by Chen Porat, Pierre Sharvit, and Shlomo Lewkowicz in 2012 and is headquartered in Misgav, Israel.

HMT Medical Technologies Ltd. has developed a novel device called "The Splitter" to enable safer and more effective aortic valve replacement procedures. The need for The Splitter arises from the fact that 1.5 million people suffer from aortic stenosis, a complex disease caused by a narrowing or hardening of the aortic valve due to calcium buildup on the heart valve flaps. The Israeli company was founded in 2021 and operates with a highly skilled team in interventional cardiology, medical device development, and commercialization. The CEO is Shlomo Lewkowicz.